NCT02582359 2022-08-24
MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age
Massachusetts General Hospital
Phase 1 Completed
Clinical Trials
6 trialsNCT02504359 2020-11-23
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
OHSU Knight Cancer Institute
Phase 1 Completed
NCT03888534 2020-09-28
Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
Takeda
Phase 1 Withdrawn
NCT02070458 2018-12-13
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
Case Comprehensive Cancer Center
Phase 1 Completed
NCT02578511 2018-02-15
Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)
Medical College of Wisconsin
Phase 1 Withdrawn
NCT01912222 2016-06-02
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction
Millennium Pharmaceuticals, Inc.
Phase 1 Completed